Anne Sullivan is Chief Business Officer (CBO) at Prilenia. In this role, Anne leads all strategic collaboration activities, including opportunities to accelerate and expand the potential impact of pridopidine. Anne brings more than 25 years of experience in the biopharmaceutical industry and with significant expertise in corporate and business development, marketing and sales, including for companies focused on neurological and neurodegenerative diseases.

Prior to joining Prilenia, Anne served as CBO at Rodin Therapeutics, a privately held clinical stage biopharmaceutical company discovering and developing first-in-class therapeutics for serious neurological diseases. Anne led the acquisition of Rodin by Alkermes plc in November 2019 and has since served as consulting CBO for multiple private and public biopharma companies.

Before joining Rodin, Anne served as Senior Vice President, Corporate Development & Operations at Sea Pharmaceuticals, LLC, a privately held, seed-stage company focused on neurological diseases. Previously, she was Vice President, Corporate Development and Licensing at Sunovion Pharmaceuticals Inc. (formerly Sepracor Inc.). In this role, she was responsible for mergers and acquisitions, licensing of products, technologies, intellectual property, and commercial partnerships in support of the company’s overall strategy. Anne was instrumental in the acquisition of Sepracor Inc. by Sumitomo Dainippon Pharma Co., Ltd. in October 2009.

Earlier in her career, Anne held management positions in marketing, market research, and sales at AbbVie. She began her career as a certified public accountant working in audit and international finance with KPMG and Wang Laboratories. Anne received an AB in economics/accounting from the College of the Holy Cross and an MBA from the Tuck School of Business at Dartmouth College.

• 

  Chief Business Officer (CBO) in Prilenia

  Pursuing Hope. Leading With Science.